Home > Insider Trading > Filing (0001493152-21-002881)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1785345	Landos Biopharma Inc.	LABP	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1493215	Rtw Investments, Lp	40 10Th Avenue, Floor 7 New York NY 10014		No	No	Yes	No
1493280	Roderick Wong	C/O Rtw Investments, Lp 40 10Th Avenue, Floor 7 New York NY 10014		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-02-04	625,000	$16.00	625,000	No	4	P	Indirect	By RTW
Common Stock	Acquisiton	2021-02-08	3,650,722	$0.00	4,275,722	No	4	C	Indirect	By RTW

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By RTW
No	4	C	Indirect	By RTW

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2021-02-08	3,650,722	$0.00	3,650,722	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

Consists of shares of common stock held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the "RTW Funds").
The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by the RTW Funds, which are investment funds managed by RTW, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaim beneficial ownership of the reported securities held by the RTW Funds, except to the extent of its or his pecuniary interest therein.
Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date.
Reflects a 1.8249-for-1 stock split of the Issuer's common stock effected on January 29, 2021.